首页> 美国卫生研究院文献>BMJ Open >Open three-stage transthoracic oesophagectomy versus minimally invasive thoraco-laparoscopic oesophagectomy for oesophageal cancer: protocol for a multicentre prospective open and parallel randomised controlled trial
【2h】

Open three-stage transthoracic oesophagectomy versus minimally invasive thoraco-laparoscopic oesophagectomy for oesophageal cancer: protocol for a multicentre prospective open and parallel randomised controlled trial

机译:开放式三阶段经胸食管切除术与微创胸腹腔镜食道切除术治疗食管癌:多中心开放和平行随机对照试验的方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionOesophageal cancer is the eighth most common cause of cancer worldwide. In 2009 in China, the incidence and death rate of oesophageal cancer was 22.14 per 100 000 person-years and 16.77 per 100 000 person-years, respectively, the highest in the world. Minimally invasive oesophagectomy (MIO) was introduced into clinical practice with the aim of reducing the morbidity rate. The mechanisms of MIO may lie in minimising the reaction to surgical injury and inflammation. There are some randomised trials regarding minimally invasive versus open oesophagectomy, with 100–850 subjects enrolled. To date, no large randomised controlled trial comparing minimally invasive versus open oesophagectomy has been reported in China, where squamous cell carcinoma predominated over adenocarcinoma of the oesophagus.
机译:引言食道癌是全球第八大最常见的癌症原因。 2009年,中国食道癌的发病率和死亡率分别为每10万人口年22.14和16.77每十万人口年。微创食管切除术(MIO)被引入临床实践,以降低发病率。 MIO的机制可能在于最大程度地减少对手术损伤和炎症的反应。有一些关于微创与开放式食管切除术的随机试验,纳入了100–850名受试者。迄今为止,在中国尚无大型比较微创与开放式食管切除术的随机对照试验,在中国,鳞状细胞癌在食管腺癌中占主导地位。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号